Effects of omentopexy combined with granulocyte colony-stimulating factor in a rabbit heart model.
OBJECTIVE
We investigated whether omentopexy combined with subcutaneously administered granulocyte colony-stimulating factor (G-CSF) reduces infarction areas and improves left ventricular dysfunction in a rabbit model of coronary occlusion and reperfusion.


METHODS
A coronary artery of a male Japanese white rabbit was ligated for 30 min and then reperfused. An omental pedicle graft was fixed onto the myocardial ischemic area after abrading the epicardium. G-CSF (10 μg kg(-1)day(-1)) was subcutaneously administered for 5 days postoperatively. Animals were assigned to groups (n = 7 per group) as follows: group N, saline; group O, omentopexy and saline; group G, G-CSF; and group OG, omentopexy and G-CSF. At 4 weeks postoperatively, left ventricular ejection fraction and left ventricular end-diastolic diameter were evaluated by echocardiography. Harvested left ventricles were stained with Evans blue and triphenyltetrazolium chloride to measure necrotic and fibrotic areas. The arteriolar density in ischemic and nonischemic areas was evaluated. At 7 days postoperatively, the intrathoracic omentum was evaluated (n = 6 per group).


RESULTS
Echocardiography at 4 weeks postoperatively revealed significant improvement in the left ventricular dysfunction of group OG. Necrosis and fibrosis in ischemic areas were significantly reduced in groups G and OG. Arteriolar density in the ischemic area and intrathoracic omentum weight were increased largely in group OG than in the other groups.


CONCLUSIONS
Omentopexy with G-CSF offers more potential benefits for the ischemic heart than G-CSF alone.
Ishida
Narihiro
N
Department of General and Cardiothoracic Surgery, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu City, Gifu 501-1194, Japan. Alpineskierjp@aol.com
Iwata
Hisashi
H
Shimabukuro
Katsuya
K
Murakami
Eiji
E
Matsumoto
Shinsuke
S
Manabe
Hideaki
H
Takemura
Hirofumi
H
D000818:Animals; D001160:Arterioles / Q000473:pathology; D001772:Blood Cell Count; D001835:Body Weight; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D000078224:Lenograstim; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000473:pathology / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000473:pathology / Q000517:prevention & control; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009852:Omentum / Q000637:transplantation*; D011182:Postoperative Care / Q000379:methods; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D013318:Stroke Volume / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000628:therapy
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim